Pseudohypoparathyroidism — PTH Resistance & Albright Hereditary Osteodystrophy

Key Points

• Low calcium + high phosphate + high PTH with normal renal function strongly suggests PTH resistance.
• Exclude vitamin D deficiency, kidney disease, and magnesium abnormalities before diagnosing PHP.
• Albright hereditary osteodystrophy includes brachydactyly, short stature, obesity, and ectopic ossification, but expression is variable.
• GNAS imprinting explains why related molecular abnormalities can produce different endocrine phenotypes.
• Calcitriol or another active vitamin D analog is the main chronic treatment.
• Oral calcium is added according to diet, symptoms, and biochemical response.
• PTH analogs are not routine therapy because the target tissue is resistant to PTH signaling.
• Screen for TSH and other hormone resistance rather than treating PHP as an isolated calcium disorder.

Algorithm

1. Confirm hypocalcemia and hyperphosphatemia and measure intact PTH.
2. Check creatinine/eGFR, 25-OH vitamin D, magnesium, and dietary/medication history to exclude common secondary causes.
3. Assess for brachydactyly, short stature, obesity, ectopic ossifications, developmental issues, and family history.
4. Repeat calcium/phosphate/PTH if the pattern is evolving or borderline.
5. Obtain phenotype-directed molecular/epigenetic testing for GNAS-pathway disease.
6. Treat symptomatic or progressive PTH resistance with calcitriol/active vitamin D plus calcium as needed.
7. Monitor serum calcium, phosphate, PTH and urinary calcium; assess for nephrocalcinosis when indicated.
8. Screen and treat associated TSH resistance, GH deficiency, hypogonadism, metabolic disease, and skeletal complications.

Clinical Synopsis & Reasoning

Pseudohypoparathyroidism (PHP) should be suspected when hypocalcemia and hyperphosphatemia occur with an appropriately elevated PTH level, normal or near-normal renal function, adequate vitamin D status, and no severe magnesium abnormality. The physiology is the inverse of primary hypoparathyroidism: the parathyroid glands make PTH, but target tissues do not respond normally. In many forms, abnormal GNAS signaling underlies hormone resistance.

The classic physical phenotype called Albright hereditary osteodystrophy includes brachydactyly, short stature, stocky habitus, early-onset obesity, round facial appearance, and subcutaneous ossifications, but not every patient has every feature. Hormone resistance can extend beyond PTH to TSH, GHRH, gonadotropins, and other pathways, depending on the molecular subtype and parental origin of the affected allele. Genomic imprinting explains why closely related GNAS abnormalities can produce different endocrine phenotypes.

PTH resistance often evolves over time. The earliest biochemical abnormality may be increasing PTH with elevated phosphate before overt hypocalcemia appears. Symptomatic hypocalcemia can cause paresthesias, tetany, cramps, seizures, prolonged QT, and in severe cases laryngospasm or arrhythmia. Chronic hyperphosphatemia and calcium-phosphate deposition can contribute to basal ganglia calcification and cataracts.

Diagnosis should first exclude more common explanations for secondary hyperparathyroidism. Vitamin D deficiency, chronic kidney disease, severe magnesium disorders, and malabsorption can all raise PTH and alter calcium/phosphate. Once true PTH resistance is established, phenotype-guided molecular testing is appropriate. The older type I/II nomenclature is less useful than identifying the underlying molecular disorder, but it remains common in educational materials.

The reasoning pivot is to recognize that high PTH in a hypocalcemic patient does not always mean vitamin D deficiency or CKD. Hyperphosphatemia with preserved renal function and a compatible phenotype points toward PTH resistance.

Treatment Strategy & Disposition

Chronic PTH resistance is treated with active vitamin D, usually calcitriol or an equivalent active analog, with oral calcium supplementation as needed. The goal is to maintain serum calcium and phosphorus in a safe range while lowering PTH toward the upper part of normal without provoking hypercalciuria. This differs from primary hypoparathyroidism because distal tubular calcium reabsorption may remain relatively preserved in PHP, so urinary calcium behavior can differ.

PTH analog therapy is not the standard treatment for PHP because the problem is resistance to PTH signaling. Serum calcium, phosphate, PTH, creatinine, and urinary calcium should be followed. Renal imaging is considered when persistent hypercalciuria raises concern for nephrocalcinosis. Acute symptomatic hypocalcemia with seizure, tetany, significant QT prolongation, or airway/cardiac instability requires IV calcium and monitored care.

Management extends beyond calcium metabolism. Patients should be screened for TSH resistance, growth hormone deficiency, hypogonadism, obesity, glucose intolerance, hypertension, sleep-disordered breathing, skeletal problems, dental disease, ectopic ossification, and neurocognitive issues depending on the phenotype. Endocrine abnormalities are treated according to the affected axis.

Because PHP-related disorders are genetically and epigenetically complex, multidisciplinary follow-up and genetic counseling are valuable. Treatment plans should avoid oversuppressing PTH, which can increase hypercalciuria risk, and should avoid assuming that normalization of serum calcium means the rest of the syndrome has been addressed.

Epidemiology / Risk Factors

• PHP and related disorders are rare and genetically heterogeneous.
• Some phenotypes become more obvious during childhood growth or adolescence.
• Endocrine resistance can evolve over time rather than being fully present at birth.
• Family history can be difficult to interpret because imprinting changes phenotype by parental origin.

Investigations

Interpreting High PTH with Hypocalcemia

Pharmacology

Prognosis / Complications

• Biochemical control of calcium/phosphate is usually achievable with active vitamin D and calcium.
• Untreated hypocalcemia can cause seizures and cardiac complications.
• Long-term morbidity often comes from obesity, skeletal disease, ectopic ossification, and additional hormone resistance.
• Early multidisciplinary surveillance improves recognition of treatable complications.

Patient Education / Counseling

• Explain that the parathyroid glands are producing hormone but the body is not responding normally.
• Teach symptoms of both hypocalcemia and hypercalcemia.
• Review the need for lifelong lab monitoring even when the patient feels well.
• Discuss the possibility of additional hormone-resistance problems and why periodic screening is needed.
• Offer genetic counseling because inheritance and imprinting can be complex.

Notes

Pseudohypoparathyroidism is a physiology-first diagnosis. If the patient is hypocalcemic, the question is whether PTH is absent, insufficient, or ineffective. A markedly elevated PTH level with hyperphosphatemia and preserved renal function points toward resistance rather than deficiency.

The disease also illustrates genomic imprinting: the same signaling pathway can produce different phenotypes depending on the molecular defect and parental origin. For clinical management, however, the first priorities are simpler—correct dangerous hypocalcemia, use active vitamin D for chronic control, avoid hypercalciuria, and screen systematically for the other endocrine and developmental features that travel with the syndrome.

References

1. International Consensus Statement — Diagnosis and management of pseudohypoparathyroidism and related disorders — Link
2. PMC Full Text — International Consensus Statement on Pseudohypoparathyroidism — Link